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Abstract
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Most known drug targets and metabolizing enzymes are located inside cells. Interactions
with these proteins are determined by intracellular unbound drug concentrations. Assessing
intracellular drug exposure is technically challenging, but essential for predicting
pharmacokinetic, pharmacological, and toxicological profiles of new drugs.
This thesis aims at establishing and applying a straightforward methodology to measure
intracellular unbound drug concentrations. This was achieved by separately measuring cellular
drug binding (fu,cell), and total intracellular drug accumulation (Kp). This allowed the calculation
of intracellular drug bioavailability (Fic), which represents the fraction of the concentration
added to the cells that is unbound in the cell interior.
The methodology was initially developed in HEK293 cells, where the Fic of 189 drug-like
compounds was measured. Binding to HEK293 cells was governed by compound lipophilicity
and was correlated with binding to more complex systems, such as hepatocytes and brain. Due to
negligible expression of drug transporters, Fic in this cell line was consistent with pH-dependent
subcellular sequestration of lipophilic cations in low pH compartments.
The methodology was then applied to study the effects of drug transporters on Fic. The
uptake transporter OATP1B1 increased the Fic of its substrates in a concentration-dependent
manner. In contrast, the Fic of P-gp substrates was decreased when P-gp was present. In human
hepatocytes, the methodology allowed the determination of Fic without prior knowledge of
transporter mechanisms or metabolic activity.
Finally, the methodology was applied to measure the impact of Fic on target binding and
cellular drug response. Intracellular concentrations of active metabolites of pro-drugs targeting
the intracellular target thymidylate synthase were in agreement with the level of binding to this
target. Further, high Fic was generally required for kinase and protease inhibitors to be active
in cellular assays.
In conclusion, the methodology can be used to predict if new drug candidates reach their
intracellular targets in sufficient amounts. Furthermore, the methodology can improve in vitro
predictions of drug clearance and drug-drug interactions, by measuring the drug available for
intracellular enzymes. Finally, this work can be expanded to other xenobiotics, e.g., to predict
their intracellular toxicity.
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In the face of overwhelming odds, I'm left with only one 
option: I'm gonna have to science the hell out of this.
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 Abbreviations 
ABC ATP-binding cassette 
ATP Adenosine triphosphate 
BCA Bicinchoninic acid 
Ccell Total intracellular drug concentration 
CETSA Cellular thermal shift assay 
Cmedium Total extracellular drug concentration 
Cu,cell Intracellular unbound drug concentration 
Cu,medium Extracellular unbound drug concentration 
CYP Cytochrome P450 
DNA Deoxyribonucleic acid 
EC50 Half maximal effective concentration 
EdU Ethynyldeoxyuridine 
EdUMP Ethynyldeoxyuridine-monophosphate 
FBS Fetal bovine serum 
FdUMP Fluorodeoxyuridine-monophosphate 
Fic Intracellular drug bioavailability 
fu,brain Fraction unbound in brain 
fu,cell Intracellular fraction unbound 
fu,hom Fraction unbound in cell homogenate 
fu,medium Extracellular fraction unbound 
fu,microsomes Fraction unbound in microsomes 
fu,plasma Fraction unbound in plasma 
GI50 Half maximal growth inhibitory concentration 
GST Glutathione-S-transferase 
HEK293 Human embryonic kidney cells 
IC50 Half maximal inhibitory concentration 
ITDRF Isothermal dose-response fingerprint 
Km Michaelis-Menten constant 
Kp Total drug accumulation ratio 
Kpuu Unbound drug accumulation ratio 
log D7.4 Octanol-water partition coefficient at pH 7.4 
log P Octanol-water partition coefficient 
MALDI Matrix-assisted laser desorption ionization 
MWt Molecular weight 
NCI National cancer institute 
OATP Organic anion-transporting polypeptide 
 PBMC Peripheral blood mononuclear cells 
P-gp P-glycoprotein 
PKIS Published kinase inhibitor set 
PSA Polar surface area 
rS Spearman's rank correlation coefficient 
SIMS Secondary ion mass spectrometry 
SLC Solute carrier 
SULT Sulfotransferase 
TFT Trifluorodeoxythymidine 
TFTMP Trifluorodeoxythymidine-monophosphate 
UGT Uridine-diphosphate-glucuronosyltransferase 
LC-MS/MS Liquid chromatography coupled to tandem mass spec-
trometry 
Vmax Maximal uptake rate 
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Introduction 
The cell interior harbors a large number of proteins of pharmacological in-
terest.1 These include not only proteins through which drugs exert their ef-
fects or toxicity, but also proteins responsible for the elimination of drug 
molecules. The interaction with these proteins is determined by the intracel-
lular levels of the drug. More specifically, it is only the unbound drug at the 
site of action that is able to engage the target and affect the biological activi-
ty.2 
Historically, unbound drug concentrations in cells or tissues have been as-
sumed to be equal to those in plasma.3 However, these concentrations are not 
always identical.4-10 Overlooking this imbalance has resulted in poor predic-
tions of in vivo drug clearance and drug-drug interactions in in vitro experi-
ments.11-16 In addition, recent analyses have shown that uncertainty of drug 
exposure at the target is one of the major causes for clinical failure of drug 
candidates.17-19 Therefore, methods that provide measurements of intracellu-
lar unbound drug concentrations have the potential to improve predictions of 
pharmacokinetics and to reduce attrition in drug development.20, 21 Previous 
research in brain, liver, and lung tissues has provided an important frame-
work on how to determine unbound drug concentrations in tissues.22-26 In this 
thesis, that work was expanded to develop a methodology to measure un-
bound drug concentrations in cell cultures. In addition, the developed meth-
odology was applied to study the factors affecting intracellular drug concen-
trations and to measure the impact of these on the cellular pharmacological 
response. 
Factors affecting cellular disposition of drugs 
Intracellular drug disposition is affected by the physicochemical characteris-
tics of the drug molecule, and by the structure of the cell and its surround-
ings (Figure 1). Transport mechanisms across the membrane and extracellu-
lar binding to proteins affect how much drug reaches the cell interior, where-
as elimination by metabolic processes reduces the amount of intracellular 
drug. Furthermore, intracellular accumulation of drug can occur when it 
binds to cellular structures, or when it is sequestered into subcellular com-
partments. The sections below present the factors influencing drug disposi-
tion in the cell in more detail. 
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Figure 1. Factors affecting cellular disposition of drugs. Transport mechanisms 
across the membrane and extracellular binding to proteins affect how much drug 
reaches the cell interior, whereas elimination by metabolic processes reduces the 
amount of intracellular drug. Furthermore, drug can accumulate intracellularly when 
it binds to cellular structures or is sequestered into subcellular compartments. 
Transport of drugs across the plasma membrane 
To access the cell interior, drug molecules must cross the lipid bilayer that 
constitutes the plasma membrane. This is achieved by passive lipoidal 
transmembrane diffusion or by carrier-mediated transport (Figure 2). 
Passive lipoidal transmembrane diffusion of drugs 
Low molecular weight lipophilic molecules enter the cell via passive lipoidal 
diffusion (Figure 2).27, 28 This process does not require energy consumption, 
as it is driven by the concentration gradient across the membrane (i.e., mole-
cules spontaneously move to the side of the membrane where their concen-
tration is lower).29 Equilibrium is reached when the intracellular unbound 
drug concentration equals that of the extracellular space.2 Therefore, passive 
transmembrane diffusion does not contribute to an accumulation of unbound 
drug in the cell interior. However, if lipoidal diffusion happens at a slow 
rate, it can limit the amount of drug that reaches the cell interior.30, 31 This 
parameter is routinely screened in drug discovery to predict drug absorption. 
Carrier-mediated transport of drugs 
Drug transport across the membrane can also be assisted by transport proteins 
(i.e., carriers).5-7 These proteins are categorized as either uptake or efflux 
transporters, depending on the direction in which they transport molecules 
through the membrane. When carrier-mediated transport occurs in favor of a 
concentration gradient, it does not expend energy and is named facilitated 
diffusion (Figure 2). Conversely, transport against a concentration gradient 
requires energy consumption and is termed active transport (Figure 2). 
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The human genome encodes for more than 400 membrane transporters.5 
These belong to two major superfamilies: the ATP-binding cassette (ABC) 
and the solute carrier (SLC) families.5, 6 Transporters belonging to the ABC 
family bind and hydrolyze ATP as their energy source.32, 33 Conversely, 
members of the SLC family that perform active transport use ion gradients 
generated by ATP-dependent primary transporters.34, 35 
Active transport can result in significant drug accumulation in the intra-
cellular space, when mediated by uptake transporters8-10, or in limited cellu-
lar exposure, when mediated by efflux transporters.36, 37 This has implica-
tions in drug discovery, because: 
1. Transporter expression varies for the different cell types in the or-
ganism. Some transporters are tissue-specific (e.g., the organic an-
ion-transporting polypeptide 1B1 (OATP1B1/SLCO1B1) is only 
expressed in hepatocytes38, 39), whereas others are expressed in 
multiple organs (e.g., P-glycoprotein (P-gp/ABCB1) is expressed 
in the liver, small intestine, kidney, blood brain barrier, and other 
tissues40); 
2. Transporter function and expression can be inhibited or enhanced 
by other xenobiotics, resulting in drug–drug interactions (e.g., 
OATP1B1 is inhibited by cyclosporine A, resulting in reduced 
elimination of its substrates, such as atorvastatin41, 42), or drug–
food interactions (e.g., naringenin, present in grape-fruit juice, re-
duces the uptake of OATP1B1 substrates43); 
3. Variations in drug transporter genes (polymorphism) can result in 
altered expression or function of transporters.44 
Some researchers have hypothesized that carrier-mediated transport is the 
sole mechanism of transport across the membrane.45-48 Still, it appears unlikely 
that transporter capacity is sufficient to support this hypothesis.27, 28, 49, 50 
 
Figure 2. Transport mechanisms for translocation of drugs across the plasma mem-
brane. Drugs can enter the cell via passive lipoidal transmembrane diffusion or via 
carrier-mediated transport. If membrane proteins transport the drug in favor of the 
concentration gradient, without energy consumption, the process is named facilitated 
diffusion. Conversely, transport against the concentration gradient, expending ener-
gy, is termed active transport. 
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Elimination of drugs from the cell interior by metabolism 
When drug molecules reach the cell interior, their intracellular levels can be 
affected by metabolizing enzymes (Figure 1). These proteins generally inacti-
vate drug molecules by hydrolysis, oxidation or reduction (Phase I metabo-
lism), or by conjugation with polar or reactive groups (Phase II metabolism).51 
In humans, the major superfamilies of drug-metabolizing enzymes are: the 
cytochrome P450 (CYP), UDP-glucuronosyltransferase (UGT), glutathione-S-
transferase (GST), and sulfotransferase (SULT) families. Many other minor 
families exist, such as serum and tissue proteases that also play an important 
role in the elimination of peptide and protein drugs.52, 53 
Drug metabolism contributes to a decrease in intracellular drug concentra-
tion. This is particularly noticeable when the metabolic rate is much higher 
than the uptake rate of the drug into the cell.31, 54 The interplay between me-
tabolizing enzymes and membrane transporters is thus recognized as a key 
aspect defining drug distribution.54, 55 Importantly, the substrate specificity of 
some transporters and enzymes significantly overlaps (e.g., many com-
pounds are substrates of both CYP3A4 and P-gp56). In addition, transporters 
play an important role in removing polar metabolites from the cell interior.57 
As with membrane transporters, multiple aspects of drug-metabolizing 
enzymes are important to consider in drug discovery: 
1. Expression of these enzymes is not ubiquitous in the organism;58 
most of the ones involved in drug metabolism are expressed in the 
intestinal wall and in the liver, with some isoforms being ex-
pressed in other tissues, such as the kidney, lung, or blood brain 
barrier; 
2. Drug metabolism can be inhibited or enhanced by other xenobiot-
ics;52 
3. Genetic polymorphism can alter the expression or function of me-
tabolizing enzymes (e.g., CYP2D6 gene duplication leads to more 
rapid metabolism of its substrates59). 
Binding of drugs to extracellular proteins 
Binding to extracellular proteins limits the amount of drug that reaches the 
cell interior, since only the unbound drug is available to enter the cell 
(Figure 1).2, 60 Protein binding is generally reversible, arising from electro-
static/hydrophobic interactions, or hydrogen bonding.60 In vivo, drug mole-
cules bind to plasma proteins, such as albumin and α1-acid glycoprotein.61 In 
vitro, some assays are run in the presence of protein to support cell cultures. 
Protein binding has direct implications on the administered drug dose.2 
Therefore, this parameter is routinely measured during drug discovery, using 
equilibrium dialysis, ultrafiltration, or ultracentrifugation.60 
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Binding of drugs to cellular structures 
Drug molecules can bind cellular constituents (e.g., proteins or nucleic acids) 
or partition into membranes (Figure 3). Binding is generally non-specific, as 
drugs interact with the cell proteome,62, 63 or partition into membranes via 
hydrophobic interactions.64-66 Non-specific binding is largely associated with 
drug lipophilicity.8, 67, 68 Binding to specific cellular structures only impacts 
drug accumulation in rare cases and is generally associated with the drug 
effect (e.g., anthracyclines bind strongly to DNA, which results in high tis-
sue concentrations69, 70; Figure 3). 
As a consequence of high levels of cellular binding, the intracellular con-
centration of some drugs can be several orders of magnitude higher than the 
extracellular one.71 However, this only reflects an increase in total drug con-
centration, and does not necessarily translate into a higher amount available 
to bind the target. 
The ability of a drug to bind to cellular and tissue components can be 
measured using equilibrium dialysis22, 72 or immobilized membrane frac-
tions66, 73, or it can be predicted from the physicochemical characteristics of 
the drug.8, 67, 74, 75 
Figure 3. Binding of drugs to cellular structures. Drugs bind non-specifically to 
cellular structures, such as membranes and proteins. In rare cases, drugs can bind to 
a specific cellular structure to a great extent, influencing the cellular distribution. 
Sequestration of drugs into subcellular compartments 
Subcellular distribution of drugs occurs as a result of: 1) pH and electro-
chemical gradients established across organelle membranes; 2) specific in-
teractions with cellular components; 3) active transport of the drug molecule 
into a specific organelle (Figure 4). The distribution is largely influenced by 
the physicochemical characteristics of the drug molecule.76 Sequestration of 
the drug in subcellular compartments can increase or decrease drug effects or 
toxicity, depending on whether the target or off-targets are localized in the 
interior of the organelle where the compound accumulates.77 
16 
Lysosomal accumulation of drugs 
Low-molecular weight lipophilic molecules with weakly basic properties 
accumulate in lysosomes, late endosomes, the Golgi apparatus, and secretory 
vesicles, due to the low intraorganelle pH (generally one to two units below 
cytosolic pH).78 Upon entering the organelle, these drugs become predomi-
nantly ionized and less likely to diffuse out, resulting in pronounced accu-
mulation (Figure 4).22, 78-84 
Large, charged molecules can also accumulate in lysosomes as a result of 
entering the cell through endocytosis or pinocytosis. These compounds are 
retained in the organelle by being intrinsically membrane impermeant, re-
quiring drug delivery strategies to escape the endosomal pathway.76, 85 
Apart from potentially affecting the efficacy of drugs, lysosomal accumu-
lation can lead to alterations in lysosomal pH, volume, or lipid content.78 
These changes might affect the distribution of concomitantly-administered 
drugs.77, 84
Mitochondrial accumulation of drugs 
In mitochondria, the inner membrane maintains a potential difference of 
approximately -180 mV.86 The high negative potential of the mitochondria 
interior leads to a charge–gradient–driven accumulation of positively-
charged compounds (Figure 4).87-89 This knowledge has been used to design 
mitochondria-targeted therapeutics.90, 91 
Nuclear accumulation of drugs 
Nuclear accumulation of flat and rigid small molecules occurs when these 
intercalate between the DNA bases (Figure 4).69, 70, 76 Intercalation also leads 
to alterations in the DNA structure that are used as therapeutic strategies.92 
Subcellular carrier-mediated transport of drugs 
Subcellular distribution of compounds might also be affected by active up-
take and efflux transporters located in the membranes of cellular organelles, 
e.g., lysosomes and mitochondria (Figure 4). This mechanism contributes to
the toxicity of some compounds, e.g., fialuridine, an antiviral drug that pro-
duces mitochondrial toxicity after being transported into the organelle by the 
equilibrative nucleoside transporter 1 (ENT1; SLC29A1).93, 94 Other members 
of the ABC95, 96 and SLC97, 98 families, capable of transporting drug-like 
compounds,99, 100 are expressed in the lysosomal membrane and influence the 
subcellular distribution of drugs. 
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Figure 4. Sequestration of drugs into subcellular compartments. Lipophilic bases 
accumulate in lysosomes by becoming predominantly charged in the acidic envi-
ronment of the organelle. Large, charged molecules are retained in the lysosome 
after entering the cell via endocytosis. Positively-charged drugs accumulate in the 
mitochondrion due to the high negative potential in the organelle interior. Flat and 
rigid small molecules intercalate between the DNA bases and, therefore, accumulate 
in the nucleus. Drug molecules might also be transported into and out of organelles 
via transporters. 
Methods to measure cellular concentrations of drugs 
Measuring drug concentrations in the cell interior is technically 
challenging.7, 20, 21 The low cellular volume (0.1–10 picoliter)101 precludes 
direct measurements, and the low number of drug molecules per cell requires 
highly sensitive methods (at 1 µM there are only 105–106 molecules/cell). 
Nevertheless, multiple approaches have been developed and are reviewed in 
the following sections, with a summary of their advantages and limitations 
(Table 1). 
Indirect determination of intracellular concentrations of drugs 
A simple approach to estimate the cellular levels of a drug is to measure a 
response elicited from an intracellular target. This response is measured in 
two setups: 1) with a recombinantly expressed target, or cell lysate (general-
ly termed biochemical assay); 2) with live cells (generally designated cellu-
lar assay). In the former case, all compound added to the assay can directly 
bind the target, whereas in the latter, the compound must permeate the mem-
brane to reach the target. A comparison of the measurements from these two 
setups provides an estimate of how much drug is bioavailable in the cell 
interior (Figure 5). 
This comparison can be made by directly measuring the engagement of 
the drug onto a target protein,102-105 or by measuring downstream events 
(e.g., consumption of a co–factor, phosphorylation of another protein, gene 
expression, or cell growth inhibition).106 
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Figure 5. Indirect determination of intracellular drug concentrations. Intracellular 
drug levels can be estimated from the potency of compounds in a biochemical assay 
(black line) and a cellular assay (green or yellow lines). In a biochemical assay, all 
drug added to the assay can directly bind the target, whereas in a cellular assay it 
must first permeate the membrane. If the compound accumulates in the cell, it will 
appear to be more potent in the cellular assay (green line). If the compound has 
restricted access to the cell interior, it will appear to be less potent in the cellular 
assay (yellow line). The magnitude of the shift will correspond to the fold-difference 
in intracellular drug concentration in relation to the extracellular drug concentration 
(i.e., how much higher or lower the intracellular drug concentration is than the ex-
tracellular one). 
Measuring drug target engagement 
Drug target engagement is one of the keystones to ensure success in discov-
ery programs.17-19 Target engagement can be measured by using displace-
ment assays102, 104, 105 or thermal shift assays.62, 63, 103, 107 
In displacement assays, a known ligand of the target competes with the 
drug of interest for available binding sites. To monitor the amount of ligand 
bound to the target, this probe is labelled with a fluorescent marker. When 
the probe is bound to the target, its rotational Brownian motion slows down 
and this results in fluorescence anisotropy (i.e., there is an unequal intensity 
of light emitted by the probe along two different polarization planes; the 
amount of light emitted along each polarization plane can be monitored to 
determine how much probe is bound to the target).102, 108 Another alternative 
to monitor the amount of bound probe is by fusing the target with a lucifer-
ase. Photons emitted by the fluorophore of the probe are captured by the 
luciferase, resulting in luminescence.104 An advantage of displacement as-
says is that they do not require labeling of the drug of interest. However, 
they require a specific ligand of the target (which is not always available) 
and that the drug tested engages the same binding site as the probe (Table 1). 
Thermal shift assays are based on the principle that a higher energy is re-
quired to denature a protein when a ligand is bound to it.109 In practice, the 
amount of soluble protein is measured after a heat challenge at several tem-
peratures in the absence or presence of the drug of interest. If the drug binds 
the target, there will be a shift in the temperature necessary to unfold the 
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protein. The assay can also be run at a constant temperature, but varying 
drug concentration, to estimate target affinity.103 Thermal shift assays do not 
require a specific probe for the target, or labeling of the tested drug. There-
fore this type of assay is amenable to high-throughput formats.107 However, 
they can only be applied to proteins that are stabilized by ligands and require 
a specific detection method for those proteins (e.g., antibodies103, 107 or mass 
spectrometry62, 63, 110). In addition, it is not possible to assure that thermal 
stabilization is a consequence of engagement of the target by the tested drug. 
For example, other compounds, such as drug metabolites, or endogenous 
ligands whose levels are increased by the drug, might instead stabilize the 
target (Table 1). 
Measuring events downstream of target engagement (biochemical and 
cellular assays) 
The amount of compound that binds a target can be inferred by monitoring 
an event related to the activity of that protein (e.g., when studying a kinase 
inhibitor, levels of a downstream phosphorylated protein or ATP levels can 
be measured111). Assays based on this principle can process a large number 
of compounds, since they do not require drug labeling. However, monitoring 
the unique activity of a protein in a cellular context is generally difficult, due 
to redundancy of cellular processes. Therefore, it is rarely possible to assure 
that the response to the drug is caused only by the target of interest (Table 
1). 
Imaging methods to measure intracellular concentrations of 
drugs 
Microscopy techniques allow not only the determination of levels of intra-
cellular drug, but also the visualization of subcellular distribution. Despite 
providing information about the organelles in which the compound might 
accumulate, these techniques measure only total drug concentrations (and 
not the fraction of compound available to bind the target). Furthermore, 
some of these techniques require labeling of the compound, which limits 
them to low-throughput formats (Table 1).  
Microautoradiography imaging 
Autoradiography provides an image of cellular distribution by revealing a 
pattern of decay emissions from a radioisotope.112 A very limited number of 
drug molecules include radioisotopes in their structure, and, consequently, 
this technique requires the radiolabeling of drug molecules.112, 113 This can be 
achieved by using the radioisotope carbon-14, with a low impact on the 
physicochemical characteristics of the drug. However, it is not possible to 
ensure that the drug is not metabolized and that the signal originates from the 
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original drug molecule. In addition, the low spatial resolution of this tech-
nique (generally on the multicellular level) limits its application (Table 1). 
Fluorescence microscopy 
Fluorescence imaging techniques with good spatial and temporal resolution 
have emerged in the last decades.114, 115 These provide an important platform 
to study subcellular drug distribution. However, only a restricted number of 
drugs display levels of autofluorescence that allow their direct visualization 
in a cellular environment.116, 117 More commonly, the drug molecules must 
be labelled with a fluorescent marker for this purpose.102, 118-122 This marker 
can be added to the drug prior to102, 118 or after121, 122 incubation with the 
cells. When added prior to the incubation, distribution can be observed in 
real time, but the presence of the label might affect the physicochemical 
characteristics of the drug. Adding the marker after the incubation (e.g., us-
ing click chemistry121, 122) requires fixation and permeabilization of the cells. 
Therefore, both approaches are prone to alter the cellular distribution of the 
studied drug. In addition, it is not possible to ensure that the drug is not me-
tabolized with the result that the marker is labeling a metabolite (Table 1). 
Raman microscopy 
Raman spectroscopy provides information on vibrational and rotational 
states of a molecule.123 Coupled to a microscope, it allows the visualization 
of distribution of drug molecules. Confocal Raman microscopy provides 
subcellular spatial resolution, but limited sensitivity and temporal resolu-
tion.124, 125 New technologies, such as hyperspectral stimulated Raman scat-
tering (hsSRS), overcome some of these limitations.126 In contrast to micro-
autoradiography and fluorescence microscopy, Raman microscopy does not 
require labeling of the drug.127 Instead, it relies on the unique vibrational 
spectral fingerprints of each molecule.123 However, when spectra fingerprints 
overlap with those of cellular components, sensitivity can be low due to high 
background noise (Table 1).126 
Mass spectrometry imaging 
Mass spectrometry allows high-sensitivity quantification of molecules due to 
its high specificity. This level of specificity is attained by precisely monitor-
ing the mass or the fragmentation pattern of a drug molecule (not requiring 
labeling).128 For this, mass spectrometry detectors require that drug mole-
cules are ionized prior to analysis. Two major ionization strategies are em-
ployed in mass spectrometry imaging: matrix-assisted laser desorption ioni-
zation (MALDI),129 and secondary ion mass spectrometry (SIMS).130, 131 
As stated in the name, MALDI requires the addition of a matrix to extract 
and crystallize the analytes, which are then ionized by absorption of energy 
from a laser source.128, 129 Matrix deposition can alter the distribution of 
compounds as they are extracted from the cell interior to the surface. In addi-
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tion, this technique provides low spatial resolution (usually multicellular) 
(Table 1). 
SIMS uses a high energy ion beam that releases and ionizes analytes from 
the surface of the sample.128, 130, 131 This technique provides very high spatial 
resolution (including z-axis resolution). However, sample preparation in-
volves fixation or freezing of samples, which can affect the cellular distribu-
tion of drugs (Table 1). 
Bulk analysis methods to measure intracellular concentrations of 
drugs 
Bulk analysis methods rely on the lysis of a large number of cells to increase 
the number of drug molecules to be analyzed. In this way, it is possible to 
overcome the detection limits of methods commonly used for the analysis of 
drugs (e.g., scintillation counting or mass spectrometry). The major draw-
backs of this approach are: 1) the loss of information about subcellular dis-
tribution of the drug; and 2) that it only provides a measure of total drug 
concentrations (Table 1). However, these limitations can be partially over-
come. 
To overcome the first limitation, and understand in which organelles the 
drug is located, it is possible to use mathematical modeling,22, 80, 82, 89 chemi-
cal inhibitors,22, 88, 132, 133 or subcellular fractionation.88, 134, 135 Mathematical 
modeling is based on the pH and electrochemical gradients established 
across certain organelle membranes. pH partition theory22, 80, 82 or the Nernst 
equation89 can be used to predict the fraction of compound trapped in a cer-
tain organelle (e.g., lysosome or mitochondrion). In addition, inhibitors of 
transporters that are responsible for the maintenance of these gradients can 
be used to gain knowledge on organelle trapping (i.e., by comparing the 
cellular uptake of the compound in the presence and absence of inhibitor).22, 
88, 133 However, these approaches are limited to subcellular compartments 
where these gradients exist or are measurable (e.g., it is difficult to model the 
distribution into the endoplasmic reticulum). An approach that can be ap-
plied to a larger number of subcellular compartments is subcellular frac-
tionation. This involves differential centrifugation of organelles. Fractiona-
tion can be performed prior to88, 134 or after135 incubation with the drug. In 
both approaches, compound distribution might be altered by the organelle 
not being in its native environment, or by the compound redistributing dur-
ing the fractionation procedure. In addition, pure organelle fractions are dif-
ficult to obtain,136 and contamination from organelles with high drug accu-
mulation can contribute to large errors. The low yields obtained from some 
fractions can also bias the results.137 
To overcome the second limitation, and be able to measure the intracellu-
lar unbound concentration of compound, it is possible to use mathematical 
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modeling,8-10, 138, 139 or to measure binding of drug to the cell.22, 139-141 Math-
ematical modeling involves a mechanistic approach where the kinetic pa-
rameters of drug distribution are fitted to experimental data.8-10, 138, 139 To 
obtain reliable results, this approach demands a large number of experiments 
(at multiple time points and concentrations), restricting it to low throughput 
formats. The other approach to determine the intracellular unbound drug 
concentration is to measure drug binding in a separate experiment and to 
subtract it from the total uptake of drug into the cell. Binding can be estimat-
ed by inhibiting all active processes,139-141 or by homogenizing the cells and 
separating the unbound drug using equilibrium dialysis.22 Inhibition of active 
processes can be done using chemical inhibitors,140, 141 or a reduced tempera-
ture.139 The use of chemical inhibitors requires that all transport and metabo-
lism mechanisms for a drug are known and can be inhibited. This limits the 
applicability of this methodology to only drugs for which all the mechanisms 
involved are known. Alternatively, lowering the temperature to halt active 
processes might also affect membrane fluidity and compound binding.142 
The approach involving cell homogenization and dialysis to measure com-
pound binding22 assumes that the destruction of the cellular context does not 
affect drug binding. In addition, the dialysis process usually requires long 
incubation times to achieve equilibrium.143 
Scintillation counting 
To determine intracellular drug concentrations, the decay emissions from a 
radioisotope can be measured using liquid scintillation counting.89, 144, 145 In 
this technique, the radiation emitted by the radioisotope (α or β particles) 
excites the electrons of an aromatic compound added during sample prepara-
tion.146 The electrons release energy when they return to the ground state. 
This energy is captured by another molecule called scintillator, which emits 
light that can be detected by a luminometer. As with microautoradiography 
imaging, this sensitive technique requires radiolabeling of the drug molecule 
(Table 1). 
Mass spectrometry 
Mass spectrometry is used for drug quantification by monitoring the precise 
mass of a drug molecule, or its fragmentation pattern. This technique re-
quires molecules to be ionized prior to entering the analyzer.147 The type of 
ionization used depends on the type of sample being analyzed, e.g., elec-
trospray ionization is one of the most commonly used ionization sources for 
small drug-like molecules.147 The ions are then conveyed to the mass analyz-
er using magnetic or electric fields. The most common types of mass analyz-
ers in use today are time-of-flight (TOF) instruments, quadrupole mass fil-
ters, ion traps, or combinations of these.148 
TOF instruments operate under the principle that the velocity of ions with 
the same charge, and identical kinetic, energy depends only on their mass.149 
 25
The time necessary to reach the detector is measured and the mass-to-charge 
ratio (m/z) of the ion can be determined. This type of instrument has high 
mass accuracy and can be used to determine the precise mass of a drug mol-
ecule. 
Quadrupole mass filters consist of four parallel rods, with each opposing 
rod pair acting together. An alternating current (AC) voltage is applied to all 
rods, with a direct current (DC) offset voltage applied between the rod 
pairs.150 This affects the trajectory of ions travelling through the quadrupole. 
For given AC and DC voltages, only ions of certain m/z pass through the 
analyzer and reach the detector.150 These voltages can be rapidly changed to 
monitor ions with different m/z. To achieve high sensitivity, these analyzers 
are generally operated with low mass resolution settings, i.e., in a way where 
it is not possible to distinguish ions of slightly different m/z.148 To increase 
their specificity, quadrupole mass filters are usually used in tandem (general-
ly, in a geometry comprising a linear series of three quadrupoles, known as a 
triple quadrupole mass spectrometer). In the first quadrupole the mass of the 
analyte (e.g., a drug) is selected (this is named the parent ion). In the second 
quadrupole, argon, neon, or nitrogen gas is used to promote the collision and 
fragmentation of ions. This quadrupole operates only under AC voltage (not 
as a mass filter) and is usually called a collision cell. In the third quadrupole, 
one of the fragment ions generated in the collision cell is selected (this is 
named the daughter ion). By monitoring a specific parent-to-daughter ion 
transition, it is possible to increase the specificity of the analyzer, since there 
is a low probability that two analytes with the same mass generate the same 
fragments. 
Ion traps accumulate ions in their interior prior to passing them to the de-
tector. Different geometries of ion traps exist, but the most commonly used 
are the quadrupole ion trap and the orbitrap. The quadrupole ion trap is used 
to increase the sensitivity of quadrupole mass filters. The operating princi-
ples are similar to those for a quadrupole, but they include an additional AC 
voltage at the two ends of the quadrupole, effectively trapping ions in this 
field.151 Orbitraps consist of a spindle-shaped electrode around which ions 
are trapped due to a balance of electrostatic attraction and centrifugal 
forces.152 By measuring the frequency of harmonic ion oscillations on an 
outer electrode that encloses the central spindle, the mass spectrum of the 
trapped ions can be obtained using fast Fourier transforms.152 As with TOF 
instruments, this type of analyzer has high mass accuracy. 
Mass spectrometry detectors are generally coupled to liquid chromatog-
raphy to isolate and concentrate the analytes, and thus increase sensitivity.153 
Since compound labeling is not required, mass spectrometry is one of the 
most versatile and frequently used techniques for the quantification of intra-
cellular drug concentrations.8-10, 22, 71, 135, 138-141  
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Aims of the thesis 
The overall aim of this thesis was to establish a general and straightforward 
methodology to measure intracellular unbound drug concentrations. 
The specific aims were: 
 
• to develop a small scale methodology for measuring intracellular 
unbound drug concentrations (Papers I and II) 
 
• to compare cellular drug binding to binding in more complex cell-
based systems, such as tissues (Papers I and II) 
 
• to assess the impact of drug transporters on intracellular unbound 
drug concentrations (Paper III) 
 
• to investigate the relationship between intracellular levels of ac-
tive metabolites of pro-drugs and target engagement (Paper IV) 
 
• to investigate the relationship between intracellular unbound drug 
concentrations and the pharmacological response in vitro (Paper 
V) 
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Methods 
Compound selection 
This thesis focused on establishing a general method to measure intracellular 
unbound concentrations of compounds. To ensure the applicability of this 
technique to all drug-like molecules, 189 compounds with a wide range of 
physicochemical characteristics were included. 
In Papers I and III, compounds were selected to cover the drug chemical 
space, and to overlap with previous studies measuring intracellular unbound 
drug concentrations.8-10, 68, 71, 140 To study transporter effects in Paper III, a 
large number of the included compounds were previously reported to be 
OATP1B1 (n = 11)39 and/or P-gp substrates (n = 22).154, 155 
In Paper II, data on brain binding (fu,brain) for 174 compounds were col-
lected from the literature.22, 156-158 A subset of compounds (n = 46) was se-
lected, ensuring that the physicochemical characteristics of these compounds 
were similar to those of a dataset of more than 800 approved drug mole-
cules.159 
In Paper IV, the hit compounds from a target engagement screen against 
thymidylate synthase were selected for the study of the intracellular kinetics 
of their metabolites. 
In Paper V, three sets of discovery compounds were included. These 
compounds belonged to the published kinase inhibitor set (PKIS),160, 161 or 
were known inhibitors of β-secretase (BACE-1) or mitogen-activated protein 
kinase 14 (p38α). Biochemical and cellular potencies were available for 
these compounds, and a large number of them displayed ‘cell drop-off’ (i.e., 
lower potency in the cellular assay than in the biochemical assay).21 
Determination of unbound drug accumulation ratio 
(Kpuu) or intracellular drug bioavailability (Fic) 
The unbound drug accumulation ratio (Kpuu) was calculated as the ratio of 
intracellular unbound drug concentration (Cu,cell) and extracellular unbound 
drug concentration (Cu,medium), according to: 
Kpuu	ൌ	
fu,cell
fu,medium
·Kp (1) 
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where fu,cell and fu,medium correspond to the intracellular and medium unbound 
drug fractions, respectively, and Kp corresponds to the ratio of total intracel-
lular (Ccell) and extracellular drug concentrations (Cmedium). Binding in the 
extracellular space was considered to be negligible (fu,medium = 1) for incuba-
tions performed in buffer. 
In Papers III and V, Kpuu was renamed to intracellular drug bioavailability 
(Fic), as a more general and descriptive term. Furthermore, the term Fic does 
not necessarily assume that compound in the medium is unbound. In this 
way, Fic represents the fraction of the concentration added to the cells that is 
unbound in the cell interior (e.g., if Fic = 0.1 and cells are incubated with a 2 
µM solution of drug, the intracellular unbound drug concentration will be 
0.2 µM). Fic was calculated as: 
 
Fic	ൌ	fu,cell·Kp (2) 
Measurement of intracellular drug binding (fu,cell) 
The fraction of drug unbound in cells (fu,cell) was measured using equilibrium 
dialysis (Figure 6). Cells were homogenized using an ultrasonic processor. 
Compounds were added to the cell homogenate individually (Paper I) or in 
cassettes (Papers II, III, and V). Homogenates were dialyzed against Hank’s 
buffered salt solution (HBSS) in a Rapid Equilibrium Dialysis device. The 
dialysis unit was incubated on an orbital shaker for 4 h at 37 °C. At the end 
of the incubation, uniform sample matrices were obtained by addition of 
blank homogenate to samples from the buffer chamber and by addition of 
blank buffer to samples from the homogenate chamber. After protein pre-
cipitation, samples were analyzed with liquid chromatography coupled to 
tandem mass spectrometry (LC-MS/MS). 
The fraction of drug unbound in the cell homogenate (fu,hom) was calculat-
ed as: 
 
fu,hom=
Cbuffer
Chom
 (3) 
where Cbuffer is the concentration of compound in the buffer chamber and 
Chom is the concentration of compound in the homogenate chamber. The fu,cell 
was calculated after correcting for homogenate dilution (D)72 according to: 
 
fu,cell=
1
D·(1/fu,hom-1)+1
 (4) 
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D was calculated as 1/(Vcell · Phom), where Vcell is the cellular volume (6.5 
µl/mg protein162), and P hom is the protein concentration of the cell homoge-
nate (in mg/µl). 
Measurement of extracellular drug binding (fu,medium) 
The fraction of extracellular unbound drug (fu,medium) was measured in a simi-
lar manner to that for the intracellular drug binding. Compounds were added 
to cell culture medium, and this solution was dialyzed against HBSS in a 
Rapid Equilibrium Dialysis device. At the end of a 4 h incubation at 37°C, 
uniform sample matrices were obtained by addition of blank cell culture 
medium to samples from the buffer chamber and by addition of blank buffer 
to samples from the cell culture medium chamber. After protein precipitation 
and quantification of drugs using LC-MS/MS, fu,medium was calculated as: 
 
fu,medium=
Cbuffer
Cmedium
 (5) 
where Cbuffer is the concentration of compound in the buffer chamber and 
Cmedium is the concentration of compound in the cell culture medium cham-
ber. 
Measurement of intracellular drug accumulation (Kp) 
Cellular drug uptake was measured by incubating cells with compound solu-
tions (Figure 6). For steady-state uptake measurements, cells were incubated 
for 45 min. At the end of the incubation, a medium sample was collected and 
cells were washed to remove any compound not associated with the cells. 
The cells were lysed to extract intracellular compound. The amount of com-
pound in cells (Acell) and the compound concentration in extracellular space 
(Cmedium) were quantified using LC-MS/MS. 
The ratio between total compound concentration in cells and in the extra-
cellular space (Kp) was calculated as: 
 
Kp=
Acell/(Vcell·Pcell)
Cmedium
 (6) 
where Vcell is the cellular volume (6.5 µl/mg protein162), and P cell is the pro-
tein amount in the cells. 
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Figure 6. Overview of determination of intracellular drug bioavailability via parallel 
measurements of intracellular drug binding (fu,cell) and intracellular drug accumula-
tion (Kp). To measure fu,cell, cells are homogenized and drugs are added to the cell 
homogenate. After equilibrium dialysis of the cell homogenate, fu,cell is determined. 
To measure Kp, drug is added to intact cells. After equilibration, the drug is quanti-
fied in the cells and in the medium to calculate Kp. 
Analytical procedures 
Drug quantification using liquid chromatography coupled to 
tandem mass spectrometry (LC-MS/MS) 
Drugs were quantified using liquid chromatography coupled to tandem mass 
spectrometry (LC-MS/MS). For most drugs, a generic 2 min gradient elution 
was used for chromatographic separation. Compounds were then analyzed 
using tandem mass spectrometry with electrospray ionization. Two unique 
parent-to-daughter transitions were monitored for each drug, and the transi-
tion with the highest signal-to-noise ratio was used for compound quantifica-
tion. 
Protein quantification using the bicinchoninic acid (BCA) assay 
To estimate cellular volume, the Pierce bicinchoninic acid (BCA) protein 
assay reagent kit was used according to the manufacturer’s instructions to 
determine the protein concentration of cell homogenates (fu,cell measure-
ments) and seeded cells (Kp measurements). Briefly, the BCA solution was 
added to cell lysates and incubated for 30 min at 37 °C. After incubation, 
absorbance was read at 562 nm. 
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Results and discussion 
Development of a methodology to measure intracellular 
unbound drug concentrations (Papers I and II) 
This work started with the development of a simple experimental methodol-
ogy to measure intracellular unbound drug concentrations. The approach was 
analogous to previous work done in brain tissue,22, 23 and consisted of a par-
allel measurement of the unbound drug fraction in cells (fu,cell) and total in-
tracellular drug concentrations (Ccell) (Figure 6). These two measurements 
were combined and normalized by the extracellular drug concentration (Cme-
dium) to obtain the intracellular drug bioavailability (Fic; previously named 
unbound drug accumulation ratio (Kpuu)). Drug quantification was per-
formed using tandem mass spectrometry. 
The initial part of this work was performed in HEK293 cells. This cell 
line was used because of its negligible expression of drug transporters and 
drug-metabolizing enzymes,163 which allowed the study of Fic without these 
confounding factors. Furthermore, incubations were performed in the ab-
sence of extracellular proteins, so that all added compound was available to 
enter the cells. In this way, the only factors affecting cellular drug disposi-
tion were intracellular binding and potential sequestration into subcellular 
compartments (Figure 1). 
Throughout this thesis, the Fic of 189 molecules was measured in these 
cells. The physicochemical properties of these compounds largely over-
lapped with those of currently approved drugs (Figure 7),159 ensuring that the 
methodology is generally applicable to new low-molecular weight chemical 
entities. In the following sections, the development of the different compo-
nents of the methodology is described in more detail. 
Unbound drug fraction in cells (fu,cell) 
The unbound drug fraction in cells (fu,cell) was measured in cell homogenates 
with equilibrium dialysis. Despite the long time required to reach equilibri-
um, the Rapid Equilibrium Dialysis apparatus used in this thesis allowed 
parallel processing of large numbers of compounds with minimal effort.143 
This apparatus allows for full automation of binding measurements. Addi-
tionally, the cassette-mode approach developed in Paper II further increased 
compound throughput.  
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Figure 7. Relative frequency distribution of physicochemical properties of approved 
drugs159 (green) and compounds for which Fic was measured in HEK293 cells 
throughout this thesis (blue). (a) log D at pH 7.4, predicted with ADMET Predictor 
v7.0 (SimulationsPlus); (b) molecular weight; (c) polar surface area; (d) major 
charge species at pH 7.4, predicted with ADMET Predictor v7.0. 
Concentration dependence of intracellular drug binding 
A requirement for using a single binding constant to measure intracellular 
unbound drug concentrations is that binding is not saturable. Saturation oc-
curs when the number of drug molecules exceeds the number of available 
binding sites.164 To ensure that intracellular binding was not saturable, the 
fu,cell of nine drugs was measured across a range of concentrations typically 
found in vivo in the cell interior. The compounds were chosen to cover a 
range of physicochemical properties typical of approved drugs (Figure 7). 
Within the range tested, fu,cell was independent of compound concentration 
(Figure 8; p >0.2–0.7, depending on the compound, based on a Kruskal-
Wallis test). This result supported the use of a single fu,cell measurement per 
compound throughout the rest of this work. 
Measurement of intracellular drug binding in cassette-mode 
Throughput of fu,cell measurements was increased by combining multiple 
drugs into a single dialysis device (cassette-mode). This was deemed reason-
able, since fu,cell was measured at submicromolar concentrations and binding 
did not appear to be saturable even at high compound concentrations 
(100 µM; Figure 8). Furthermore, the fu,cell of a subset of 14 drugs was not 
significantly different for the incubations with individual compounds and 
those in cassette-mode (Figure 9a; rS = 0.99). 
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Figure 8. Concentration dependence of intracellular drug binding (fu,cell) in HEK293 
cells. Negatively charged compounds at pH 7.4 are represented by triangles, neutral 
compounds by circles, and positively charged compounds by squares. Compounds 
were color coded by lipophilicity (low lipophilicity (log D7.4 ≤0) in green; interme-
diate lipophilicity (log D7.4: 1–3) in orange; high lipophilicity (log D7.4 >3) in red). 
 
For all subsequent measurements of intracellular drug binding, com-
pounds were randomly assigned to at least three different cassettes, with a 
total of six compounds per cassette. This minimized the risk of potential 
interactions between pairs of compounds, due to the low probability of two 
interacting compounds being assigned to the same three cassettes. To further 
ensure the quality of fu,cell measurements, atorvastatin and lopinavir were 
added to all cassettes as controls. The fu,cell of these drugs did not differ sig-
nificantly each time it was measured (Figure 9b; p = 0.79 based on a Krus-
kal-Wallis test; average deviation from median fu,cell was 1.3-fold for both 
atorvastatin and lopinavir), indicating that the assay was stable over time. 
 
 
Figure 9. Cassette-mode measurement of intracellular drug binding (fu,cell) in 
HEK293 cells. (a) Comparison between drug binding measured in incubations with 
individual compounds and in cassette-mode. Negatively charged compounds at 
pH 7.4 are represented by triangles, neutral compounds by circles, and positively 
charged compounds by squares. (b) fu,cell of atorvastatin (blue) and lopinavir (or-
ange) measured in multiple cassettes over time. Dashed line represents median fu,cell 
of all measurements. 
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Molecular determinants of intracellular drug binding 
To investigate the molecular determinants of fu,cell in HEK293 cells, a multi-
variate structure-property relationship was developed using partial least-
squares projection.165 fu,cell was predicted from molecular descriptors with an 
average 3.5-fold error (rS = 0.75; Figure 10a). In agreement with previous 
observations,8 lipophilicity (log P and log D7.4) correlated strongly with fu,cell, 
with higher binding observed for the more lipophilic compounds (Figure 
10b). Furthermore, binding also appeared to be higher for molecules with a 
large surface for interaction, i.e., rigid molecules stretched out in two dimen-
sions (Balaban distance connectivity index J, number of unsaturated bonds). 
Conversely, negative charge and aromaticity (number of distinct π systems, 
π partial atomic charges) were associated with decreased binding (Figure 
10). Altogether, this suggested that fu,cell may be driven mainly by partition-
ing to cellular membranes. This is supported by the higher binding of lipo-
philic compounds with a large surface for interaction (with higher affinity to 
membrane lipids). The lower binding of negatively-charged and aromatic 
compounds is possibly due to electrostatic repulsions between the electron-
rich groups in the drug molecules and the negatively-charged membrane 
lipids. Although intracellular protein binding might also partly contribute to 
fu,cell, recent studies62, 63 have shown that drugs bind only a small fraction of 
the cell proteome (e.g., staurosporine, a promiscuous kinase inhibitor, with 
high lipophilicity, was bound to only 0.8% of the analyzed proteins).62 
 
 
 
Figure 10. Molecular determinants of intracellular drug binding (fu,cell) in HEK293 
cells. (a) Predictions of fu,cell from a multivariate structure-property relationship 
using partial least-squares projection. Negatively charged compounds at pH 7.4 are 
represented by triangles, neutral or zwitterionic compounds by circles, and positive-
ly charged compounds by squares. Solid line represents a perfect prediction; dashed 
lines represent a ten-fold error in prediction. (b) The most influential descriptors in 
the multivariate prediction. Descriptors with negative coefficients had higher values 
in drugs with high binding, and descriptors with positive coefficients had higher 
values in drugs with low binding. 
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Comparison of intracellular drug binding to binding in other systems 
Drug binding to HEK293 cells was compared to binding in other systems of 
varying complexity. 
Comparison to plasma protein binding 
First, fu,cell was compared with plasma protein binding (fu,plasma),166 a parame-
ter regularly measured in the early stages of drug discovery. There was a 
poor correlation between these two parameters (Figure 11a; rS = 0.51, 
n = 58), with most compounds binding more extensively to cellular struc-
tures than to plasma proteins. These differences were expected, since bind-
ing in plasma is mainly driven by interactions with proteins,61 while 
HEK293 cells are composed of a mixture of all cell constituents including 
proteins, membranes, and DNA. 
Comparison to binding in liver-derived systems 
Next, fu,cell was compared with binding to other cell-based systems, such as 
liver microsomes and hepatocytes. Binding to liver microsomes 
(fu,microsomes),30, 68, 140, 167-175 a purified fraction of liver homogenates, strongly 
correlated with fu,cell in HEK293 cells (Figure 11b; rS = 0.88, n = 14). Simi-
larly, binding to hepatocytes (fu,cell hepatocytes)30, 68, 71, 138, 140, 144, 145, 175-177 corre-
lated with binding to HEK293 cells (Figure 11c; rS = 0.74, n = 43). However, 
binding was more extensive in the liver-derived systems. In microsomes, 
binding was on average 4.9-fold higher, whereas in hepatocytes, binding was 
on average 2.5-fold higher. These differences can be attributed to the higher 
protein and lipid levels present in hepatocytes, which are approximately 2- to 
2.5-fold higher than in embryonic kidney cells, based on a comparison of the 
tissues of origin of the two cell types: liver (for hepatocytes) and embryonic 
kidney (for HEK293 cells).178 
Comparison to binding to brain 
Finally, fu,cell was compared with brain binding (fu,brain).22, 156-158 Surprisingly, 
despite the higher levels of lipids present in the brain (six-fold higher than in 
the embryonic kidney), fu,brain values were similar to those of fu,cell (Figure 
11d; rS = 0.91, n = 46). This might have arisen as a consequence of compar-
ing two systems at different levels: organ (brain) and cell (HEK293 cells). 
The extracellular space constitutes approximately 20% of the brain 
volume,179 and contributes to a dilution of the homogenate used for fu,brain 
measurements. Nevertheless, the strong correlation between these two sys-
tems can be used to predict fu,brain in an inexpensive way without the use of 
experimental animals. 
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Figure 11. Intracellular drug binding (fu,cell) in HEK293 cells and binding in other 
systems. Comparison between fu,cell in HEK293 cells and: (a) plasma protein binding 
(collected from literature166); (b) binding to liver microsomes, corrected for the 
dilution that occurs during the preparation of microsomes from liver tissue (collected 
from literature30, 68, 140, 167-175); (c) binding to human and rat hepatocytes (measured 
in-house for human hepatocytes, and collected from literature for rat hepatocytes30, 
68, 71, 138, 140, 144, 145, 175-177); (d) binding to brain (collected from literature22, 156-158). 
Negatively charged compounds at pH 7.4 are represented by triangles, neutral or 
zwitterionic compounds by circles, and positively charged compounds by squares. 
Intracellular drug accumulation ratio (Kp) 
The intracellular drug accumulation ratio (Kp) was measured after incuba-
tion of the cells with drug. To determine the time required to achieve steady-
state accumulation, uptake experiments with nine compounds, covering a 
wide range of physicochemical properties, were stopped at different time 
points (the compounds used were the same as the ones in ‘Concentration 
dependence of intracellular drug binding’ experiments). High lipophilicity 
and the presence of basic groups increased the time required for equilibrium 
(Figure 12). Nevertheless, 45 min appeared to be sufficient to reach equilib-
rium for all compounds (Figure 12). 
As with cellular drug binding experiments, atorvastatin and lopinavir 
were used as controls to ensure the quality of Kp measurements. These com-
pounds were run in parallel with the other assayed compounds. The Kp of 
these drugs did not differ significantly each time it was measured (Figure 13; 
p = 0.97 based on a Kruskal-Wallis test; average deviation from median Kp 
was 1.6-fold for atorvastatin and 1.3-fold for lopinavir). 
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Figure 12. Time dependence of intracellular drug accumulation (Kp) in HEK293 
cells for (a) candesartan, (b) simvastatin acid, (c) repaglinide, (d) caffeine, (e) on-
dansetron, (f) lovastatin, (g) metoprolol, (h) diltiazem, and (i) astemizole. Negative-
ly charged compounds at pH 7.4 are represented by triangles, neutral compounds by 
circles, and positively charged compounds by squares. Compounds are color coded 
by lipophilicity (low lipophilicity (log D7.4 ≤0) in green; intermediate lipophilicity 
(log D7.4: 1–3) in orange; high lipophilicity (log D7.4 >3) in red). The lines represent 
the fit to a one-site binding model. 
 
 
Figure 13. Controls for intracellular drug accumulation (Kp) experiments in 
HEK293 cells. Kp of atorvastatin (blue) and lopinavir (orange) measured in parallel 
to other compounds. Dashed line represents median Kp of all measurements. 
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Intracellular drug bioavailability (Fic) 
After determination of the intracellular drug binding (fu,cell) and accumulation 
(Kp), intracellular bioavailability (Fic) was calculated as the product of these 
parameters. Fic was related to the charge of the compound, with negatively-
charged compounds displaying a median Fic of 0.43, neutral compounds of 
1.0, and positively-charged of 3.4 (Figure 14a; p <0.0001 based on a Krus-
kal-Wallis test; a post hoc analysis using Dunnett’s test found significant 
differences between all groups). The higher value for the basic drugs is con-
sistent with the trapping of charged species in acidic subcellular organelles, 
such as endosomes and lysosomes, while the lower-than-unity value for ac-
ids is to be expected because of the pH gradient across the plasma membrane 
(Figure 14b). Since HEK293 cells express negligible amounts of drug trans-
porters and metabolizing enzymes,163 it was possible to accurately predict the 
median Fic of each charge category using pH partition theory (Figure 14a). 
In the following sections, the methodology was applied to other cell 
types: first to evaluate the impact of drug transporters on Fic, and then to 
assess the impact of Fic on drug target engagement and cellular pharmacolog-
ical responses. 
 
 
 
 
Figure 14. Impact of charge on intracellular drug bioavailability (Fic) in HEK293 
cells. (a) Distribution of Fic for negatively charged compounds at pH 7.4 (orange; 
n = 17), neutral and zwitterionic (blue; n = 127), and positively charged compounds 
(red; n = 45). The line in the boxes represents the median; edges of the boxes repre-
sent the first and third quartiles; and whiskers represent the 5th and 95th percentile. 
Dashed lines represent predictions from a pH partition model. (b) Schematic repre-
sentation of cellular distribution for acidic and basic drugs, taking into consideration 
that the permeability of charged species is lower than the uncharged species. Low 
pH subcellular compartments (pH 5) represent endosomes and lysosomes. 
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Impact of drug transporters on intracellular unbound 
drug concentrations (Paper III) 
The impact of drug transporters on intracellular unbound drug concentrations 
was studied by first measuring Fic in cell lines expressing the organic anion-
transporting polypeptide 1B1 (OATP1B1; SLCO1B1—an uptake trans-
porter), or P-glycoprotein (P-gp; ABCB1—an efflux transporter). Next, the 
impact of multiple transporters was assessed by measuring Fic in a more 
complex system—freshly isolated human hepatocytes. These studies used a 
compound set of physicochemically-diverse molecules and included com-
pounds previously reported to be OATP1B1 (n = 11)39 and/or P-gp sub-
strates (n = 22)154, 155. 
Impact of OATP1B1 on Fic 
To exemplify the influence of an uptake transporter on intracellular unbound 
drug concentrations, Fic in HEK293 cells transfected with OATP1B1 was 
compared to that in HEK293 cells transfected with an empty vector (Figure 
15a). Overall, the Fic of OATP1B1 substrates was on average 2.9-fold higher 
in the OATP1B1-transfected cells (range: 1.1 – 9.8-fold; p = 0.001 based on 
a Wilcoxon matched-pairs signed rank test; Figure 15b). Conversely, non-
substrates of OATP1B1 showed a similar Fic in both cell lines (range: 0.57 – 
1.9-fold difference between OATP1B1- and mock-transfected cells; p = 0.06 
based on a Wilcoxon matched-pairs signed rank test). The impact of the 
uptake transporter decreased with increasing compound lipophilicity 
(rS = -0.63), likely reflecting the increase in transmembrane diffusion with 
increased lipophilicity.27, 180, 181 
To investigate if the differences observed were caused by an active uptake 
mediated by OATP1B1, the Fic of four substrates (atorvastatin, pitavastatin, 
fluvastatin, and simvastatin acid) was measured across a range of concentra-
tions (Figure 15c-f). In mock-transfected cells, Fic was independent of com-
pound concentration for all substrates. This indicated that passive permeabil-
ity was the main uptake mechanism in these cells. In contrast, Fic decreased 
in the OATP1B1-transfected cells as the compound concentration increased, 
approaching levels in mock-transfected cells at higher concentrations. The 
concentrations at which Fic was half of its maximal value were close to pre-
viously reported Km values for OATP1B1-mediated transport of the respec-
tive substrates,182-184 indicating transporter saturation and an ensuing domi-
nance of a passive mechanism. 
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Figure 15. Impact of the uptake transporter OATP1B1 on intracellular bioavailabil-
ity (Fic). (a) Schematic representation of cell types used: mock-transfected HEK293 
cells express negligible levels of relevant drug transporters163; OATP1B1-
transfected HEK293 cells express OATP1B1. (b) Comparison between Fic in mock-
transfected and OATP1B1-transfected HEK293 cells at 0.1 µM compound concen-
tration. Substrates of OATP1B1 are highlighted in green. Negatively charged com-
pounds at pH 7.4 are represented by triangles, neutral or zwitterionic compounds by 
circles, and positively charged compounds by squares. (c-f) Concentration-
dependence of Fic in OATP1B1-transfected HEK293 cells (green squares), fitted 
with a sigmoidal model (green line), and mock-transfected HEK293 cells (blue cir-
cles) for atorvastatin (c), pitavastatin (d), fluvastatin (e), and simvastatin acid (f). 
Impact of P-gp on Fic 
Next, the effect of an efflux transporter on Fic was evaluated in MDCK cells 
transfected with human P-gp and in wild-type MDCK cells where back-
ground endogenous canine P-gp was knocked-out with CRISPR/Cas9 tech-
nology (cMdr1-KO; Figure 16a).185 Fic of P-gp substrates was, on average, 
2-fold lower in P-gp-expressing than in cMdr1-KO cells (range: 0.94 – 
20-fold lower in P-gp transfected than cMdr1-KO cells; p <0.001 based on a 
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Wilcoxon matched-pairs signed rank test; Figure 16b). For compounds not 
previously described as substrates, Fic was more similar in the two cell lines 
(range: 1.1 – 3.0-fold difference between cMdr1-KO cells and P-gp trans-
fected cells). Overall, lipophilic molecules showed lower Fic in P-gp trans-
fected cells (rS = -0.60), independently of being previously described as sub-
strates or not. This possibly reflects that compounds bind P-gp from within 
the inner leaflet of the plasma membrane,186, 187 and suggests that additional 
compounds in the dataset may be substrates of P-gp. 
As for OATP1B1 substrates, the concentration-dependence of Fic of 
simvastatin acid was measured. As expected, Fic in P-gp-expressing cells 
was lower than that in cMdr1-KO cells at low concentrations and ap-
proached it at higher concentrations (Figure 16c). Surprisingly, Fic decreased 
with increasing compound concentration in both the P-gp-transfected and 
cMdr1-KO cells, suggesting that there are additional active uptake mecha-
nisms present in these cells. To better understand these observations, cellular 
drug accumulation was simulated using two simple kinetic models: 1) in-
cluding both active uptake and active efflux mechanisms (corresponding to 
P-gp-transfected cells); and 2) including the uptake mechanisms only (corre-
sponding to cMdr1-KO cells; Figure 16a). The simulations were in agree-
ment with the experimental observations for a compound with high passive 
permeability, medium affinity (Km = 10 µM) for an uptake transporter, and 
lower affinity (Km = 100 µM) for an efflux transporter, with both transport-
ers having comparable (high) transport capacities (Vmax) (Figure 16d). This 
matched previous observations for simvastatin acid, which has a high pas-
sive permeability, a high affinity for uptake transporters, and a low affinity 
for efflux transporters.188-190 
Fic in primary human hepatocytes 
Finally, the impact of multiple transporters and metabolizing enzymes on Fic 
was studied in human hepatocytes in two different culturing conditions 
(Figure 17a): 1) freshly isolated cells (in suspension) that express similar 
levels of transporters and metabolizing enzymes as those in the human liver; 
and 2) cells cultured for 24 h (in monolayer format) that show a significant 
down-regulation of many important transporters and enzymes due to cell 
dedifferentiation.191-194 On average, Fic was 5.7-fold lower in freshly isolated 
suspension hepatocytes than in monolayer hepatocytes cultivated for 24 h 
(Figure 17b; p = 0.0002 based on a Wilcoxon matched-pairs signed rank 
test). This was in agreement with a higher gene expression of efflux trans-
porters and enzymes in suspension hepatocytes.191-194 These proteins are 
associated with the removal of compounds from the cell interior, which leads 
to a lower Fic. This was particularly evident for atorvastatin, cerivastatin, 
fluvastatin, imipramine, propranolol, ritonavir, and simvastatin acid, which 
showed 4.9 – 15-fold lower Fic in suspension hepatocytes. 
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Figure 16. Impact of the efflux transporter P-gp on intracellular bioavailability (Fic). 
(a) Schematic representation of cell types used: MDCK cells where canine P-gp has 
been knocked-out using CRISPR/Cas9; MDCK cells expressing canine and human 
P-gp. (b) Comparison between Fic in P-gp-knockout MDCK cells and in P-gp-
transfected MDCK cells at 0.5 µM compound concentration. Negatively charged 
compounds at pH 7.4 are represented by triangles, neutral or zwitterionic com-
pounds by circles, and positively charged compounds by squares. Substrates of P-gp 
are highlighted in orange. (c) Concentration-dependence of Fic in P-gp-transfected 
(orange squares), and P-gp-knock-out MDCK cells (blue circles). (d) Kinetic cell 
model simulations that best described experimental observations of concentration-
dependence Fic for simvastatin acid (conditions: passive permeability = 10 × 10-6 
cm/s; Vmax,uptake = 1000 pmol/min/mg protein; Km,uptake = 10 µM; Vmax,efflux = 1000 
pmol/min/mg protein; Km,efflux = 100 µM). 
 
Figure 17. Impact of multiple transporters and metabolizing enzymes on intracellular 
bioavailability (Fic). (a) Schematic representation of hepatocyte cultures used: fresh-
ly-isolated human hepatocytes in suspension express higher levels of drug transport-
ers and metabolizing enzymes; hepatocytes cultured for 24 h in monolayer format 
show downregulation of most drug transporters and metabolizing enzymes.191, 192 
(b) Comparison of Fic in suspension hepatocytes and in hepatocytes cultured in 
monolayer format. Negatively charged compounds at pH 7.4 are represented by tri-
angles, neutral compounds by circles, and positively charged compounds by squares.  
 43
Influence of intracellular drug concentrations on target 
engagement (Paper IV) 
The methodology developed in this thesis was used to evaluate the impact of 
intracellular drug levels on target engagement. First, a compound library (n = 
10,928) was screened for the capacity to bind thymidylate synthase in K562 
cells, using the cellular thermal shift assay (CETSA).103, 107 Among the hits 
were pyrimidine-based nucleosides and their analogs, such as 5-fluorouracil, 
floxuridine, trifluorodeoxythymidine (TFT), and ethynyldeoxyuridine 
(EdU). These compounds are known inhibitors of thymidylate synthase that 
require intracellular activation to the monophosphate form prior to interac-
tion with the enzyme (Figure 18a).195, 196 To study the kinetics of activation 
of the four hit compounds, CETSA was then performed after various pre-
incubation times. In parallel, the intracellular levels of the hit compounds 
and their metabolites were monitored. 
For floxuridine, CETSA data showed target stabilization at low nanomo-
lar concentrations after only 10 minutes of pre-incubation (Figure 18b). The 
potency increased during the first 2 hours and persisted throughout the ex-
periment. This was consistent with the intracellular appearance of the active 
species fluorodeoxyuridine-monophosphate (FdUMP), which was measure-
able after 10 minutes and increased during the first hours of incubation 
(Figure 18c). In contrast, the CETSA response of 5-fluorouracil (a pro-drug 
of floxuridine) increased slowly during the first 6 hours (Figure 18b), with 
undetectable intracellular levels of FdUMP, revealing that the enzymatic 
conversion of 5-fluorouracil to FdUMP is much slower than for floxuridine.  
The intracellular metabolism of TFT was similar to that observed for 
floxuridine (Figure 18d). This was consistent with a build-up of trifluorode-
oxythymidine-monophosphate (TFTMP) and binding to thymidylate syn-
thase in the first hours. Both TFTMP and FdUMP form a covalent complex 
with thymidylate synthase,195, 197-199 in line with a persistent target engage-
ment even after a decrease in their intracellular levels (Figure 18c and d). 
EdU behaved differently, with a maximal CETSA response at the earliest 
time-point. The decrease of CETSA response with time was accompanied by 
a decrease of intracellular levels of the active form ethynyldeoxyuridine-
monophosphate (EdUMP) (Figure 18e). This profile might have arisen as a 
consequence of EdUMP forming a non-covalent complex with thymidylate 
synthase (i.e., target stabilization decreased with decreased intracellular con-
centrations of EdUMP due to further metabolism; Figure 18a).200 
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Figure 18. Impact of intracellular concentrations of the active metabolites of pro-
drugs on target engagement. (a) Schematic representation of activation of 
5-fluorouracil. Prior to binding to thymidylate synthase, 5-fluorouracil is converted 
to floxuridine by thymidine phosphorylase, which is then phosphorylated by thymi-
dine kinase to floxuridine monophosphate (FdUMP).195 Alternatively, floxuridine 
can be directly administered to avoid the first metabolic step. (b) Thymidylate syn-
thase engagement (CETSA) for floxuridine (red triangles) and 5-fluorouracil (blue 
circles), measured at different incubation times (from 10 min (lighter colors) to 6 h 
(darker colors)). (c-e) Comparison of CETSA potency (green) and intracellular lev-
els of active metabolites of thymidylate synthase inhibitors (blue) at different incu-
bation times: (c) incubation with floxuridine and intracellular levels of FdUMP; (d) 
incubation with trifluorodeoxythymidine (TFT) and intracellular levels of trifluoro-
deoxythymidine-monophosphate (TFTMP); (e) incubation with ethynyldeoxyuridine 
(EdU) and intracellular levels of ethynyldeoxyuridine-monophosphate (EdUMP). 
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Impact of Fic on cellular pharmacological response 
(Paper V) 
The impact of intracellular unbound drug concentrations on the cellular 
pharmacological response was evaluated with three compound sets: 1) a 
subset of compounds from the published kinase inhibitor set (PKIS);160, 161 
2) a set of β-secretase 1 (BACE-1) inhibitors; and 3) a set of mitogen-
activated protein kinase 14 (MAPK14 or p38α) inhibitors. 
Published kinase inhibitor set (PKIS) 
The published kinase inhibitor set (PKIS) includes 367 compounds that have 
been screened in the Nanosyn kinase panel (biochemical screen) and in the 
NCI-60 cell panel (cellular screen; Figure 19a).161 A subset of compounds 
with potential to inhibit cell growth was selected from this library. For this, 
compounds were grouped based on their biochemical affinity profiles, using 
hierarchical clustering with complete linkage (Figure 19a).201 Then, clusters 
were selected that contained at least one active compound (pGI50 >6) in more 
than half of the NCI-60 cell lines. This resulted in three clusters of molecules 
originally targeting intracellular kinases involved in the cell cycle, such as 
cyclin-dependent kinase 2 (CDK2),202 glycogen synthase kinase 3 (GSK3), 
or polo-like kinase 1 (PLK1).203 Despite showing similar biochemical inhibi-
tion profiles, compounds within each cluster displayed very different cellular 
potencies (Figure 19a). To assess if these discrepancies were caused by dif-
ferences in the levels of compound available at the target, Fic was measured 
in HEK293 cells. This was a cell line not included in the NCI-60 panel, but 
with a gene expression profile close to that of an average cell line from this 
panel, allowing the use of the average of pGI50 across the 60 cell lines as a 
measure of compound potency. 
Fic was correlated with potency, in that cellular potency increased with a 
higher Fic (rS=0.64; Figure 19b). To help explain the cellular activity of com-
pounds, a classification model was established (Figure 19c). In this model, 
compounds were classified based on their Fic and cellular potency. The Fic 
and cellular potency thresholds can be adjusted to reflect the tolerated Fic and 
the desired potency of the discovery program (for this set, they were fixed at 
Fic = 1 and pGI50 = 6). Class 1 compounds were active in cellular assays and 
their concentrations at the target were equal to or higher than the nominal 
concentration added to the cells; class 2 compounds were active in cells, 
despite their access to the target being restricted; class 3 compounds were 
inactive in cells, even though they had high Fic; and class 4 compounds were 
not active in cells and displayed low Fic. 
For this compound set, most compounds (71%) belonged to either class 1 
(23%) or class 4 (48%) (Figure 19c). Compounds in class 1 are active be-
cause of their high Fic, while compounds in class 4 are inactive because their 
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access to the target is limited. Furthermore, only 18% of compounds in this 
set were in class 2 and 11% were in class 3. Compounds appear in class 2 if 
they are promiscuous, or if they have high biochemical potency.204 Class 3 
compounds have either low biochemical potency, or their target protein is 
not relevant for the cellular response being studied.205 
 
 
 
 
Figure 19. Intracellular bioavailability (Fic) of compounds from the published kinase 
inhibitor set (PKIS). (a) Biochemical and cellular data for PKIS. Each row repre-
sents one compound and each column represents one kinase of the Nanosyn panel or 
one cell line of the NCI-60 panel. Colors represent the potency of the compounds 
(pIC50 for kinases and pGI50 for cell lines). In the left panel, compounds, kinases and 
cell lines are sorted alphabetically. In the right panel, compounds were clustered 
based on their biochemical data and cell lines were sorted from the most potent to 
the least potent for each compound for better visualization of the cell growth inhibi-
tion potential of each molecule. Selected compounds are highlighted in blue and 
targets for which these compounds were initially developed are highlighted in grey. 
(b) Relationship between average pGI50 in the NCI-60 panel and Fic in HEK293 
cells. (c) Classification model based on pGI50 and Fic, with thresholds at Fic = 1 and 
pGI50 = 6. 
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β-secretase 1 (BACE-1) inhibitors 
A set of 25 BACE-1 inhibitors was used to further study the impact of Fic on 
cellular drug response. This set displayed strong ‘cell drop-off’,21 i.e., com-
pounds showed on average one order of magnitude lower potency in a cellu-
lar screen than in a biochemical assay. 
Fic of these compounds was measured in SH-SY5Y cells using a similar 
setup as in the cellular potency assay. As expected, these compounds dis-
played low Fic (median = 0.27, interquartile range: 0.15 – 0.68). Using the 
classification model introduced for the PKIS dataset (with thresholds set at 
Fic = 1 and cellular pIC50 = 6), most of these substances belonged to class 2 
(56%; low Fic, high cellular pIC50) and class 4 (24%; low Fic, low cellular 
pIC50). The unexpectedly high number of class 2 compounds was justified by 
the high biochemical potency of these compounds, i.e., in spite of limited 
access to the target, the compounds were still active in cells due to their high 
biochemical potency. In fact, 7 of the 14 compounds in this category were 
among the strongest BACE-1 inhibitors, with a pIC50 ≥8, two orders of mag-
nitude higher than the cell potency cut-off. 
Mitogen-activated protein kinase 14 (p38α) inhibitors 
A set of 35 p38α inhibitors was used to explore the reasons for the low Fic of 
some of the compounds. Similarly to the BACE-1 inhibitors, these com-
pounds displayed ‘cell drop-off’.21 
Fic of these compounds was measured in peripheral blood mononuclear 
cells (PBMC), analogous to the setup of the cellular screen. As anticipated 
from the generalized presence of ‘cell drop-off’, all compounds displayed 
low Fic (median = 0.088, interquartile range: 0.069 – 0.19) and belonged to 
classes 2 (74%) and 4 (26%). Class 2 compounds were strong inhibitors of 
p38α (pIC50 in biochemical assay ≥7, two orders of magnitude more potent 
than in the cellular assay). Further studies showed that the Fic and cellular 
potency of these compounds was hampered by the presence of extracellular 
proteins in the cell culture medium (Figure 1), and by active transport mech-
anisms (Figure 2). 
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Conclusions 
In this thesis, a novel methodology was developed for the measurement of 
intracellular unbound drug concentrations. This methodology was applied to 
nearly 200 drug-like compounds in multiple cell types (including primary 
liver cells, and blood cells). Cellular drug-binding was correlated across 
multiple cell systems (including tissues). Furthermore, intracellular unbound 
drug concentrations were affected by drug transporters. More specifically, 
OATP1B1 increased the cellular levels of its substrates, whereas P-gp con-
tributed to a decrease of intracellular concentrations of its substrates. Addi-
tionally, target engagement was correlated with intracellular concentrations 
of active metabolites of pro-drugs targeting the intracellular target thymi-
dylate synthase. Finally, low intracellular unbound concentrations provided 
an explanation for the lack of cellular activity of drugs targeting intracellular 
proteins. In summary, the methodology developed here can be applied in 
drug discovery to predict if compounds reach their intracellular targets. Ad-
ditionally, by providing information on the amount of drug available to be 
metabolized or excreted, this methodology provides important information 
for in vitro predictions of drug elimination. 
From the work presented herein, it can be concluded that: 
 
• the methodology developed can be used for drug-like compounds 
in a wide range of cell types to provide information about the 
amount of drug bioavailable in the cell interior 
 
• a commonly used cell line, such as HEK293 cells, can be used to 
predict binding in more complex cell-based systems 
 
• drug transporters can affect intracellular unbound drug concentra-
tions and hence drug activity or elimination 
 
• the amount of unbound drug that reaches intracellular targets in-
fluences target engagement and the subsequent response 
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Future perspectives 
This thesis describes the development of a new methodology to measure 
intracellular unbound drug concentrations. In this work, the methodology 
was applied to small molecule drugs, generally within the boundaries of 
Lipinski’s rule-of-five. However, it should be possible to extend its applica-
tion to other xenobiotics, such as environmental toxins and pollutants, to 
predict their intracellular toxicity. This technique might also be applied to 
larger compounds, such as peptides or macrocycles. These compounds gen-
erally have low intracellular bioavailability and require formulation strate-
gies to reach the interior of the cell. The methodology presented here could 
act as a simple tool for the screen of effective formulations. 
The results in this thesis suggest that fu,cell is mainly driven by membrane 
partition, however further studies on which cellular structures drugs bind to 
need to be performed. Such studies could provide an explanation for the 
observed correlation between binding to a simple cell line and binding to 
more complex systems, e.g., tissues. Furthermore, it could open the possibil-
ity for accurate predictions of drug binding to any cell-based system of 
known composition, resulting in a reduction of experimental efforts and an 
increased throughput of determination of intracellular unbound drug concen-
trations. To achieve this goal, the composition of different cell types can be 
studied together with measurements of cellular drug binding in those cells. 
Alternatively, it is also possible to measure binding to isolated cell compo-
nents (e.g., phospholipids, proteins, and nucleic acids). Further, technologies 
combining the cellular thermal shift assay (CETSA) with mass spectrometry-
based proteomics could be used to provide information on which proteins 
drugs are bound to. 
In parallel to the measurement of intracellular drug binding, the method-
ology developed in this thesis requires the measurement of total intracellular 
drug concentrations. Since the technique used relies on bulk analysis, infor-
mation about the precise location of the drug in the cell interior is lost. 
Methods that provide this information can be used together with the method-
ology developed in this thesis to understand where the drug is located. These 
include, for example, imaging methods with high spatial resolution, such as 
super-resolution fluorescence microscopy or secondary ion mass spectrome-
try imaging (SIMS). If these techniques could be used on large datasets, it 
could be possible to find the molecular properties that determine the subcel-
lular distribution of drugs to individual organelles. This could allow the de-
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sign of drugs that accumulate in compartments where their target is located, 
while avoiding accumulation in other organelles. 
The increased knowledge on protein expression made possible by ad-
vances in mass spectrometry-based proteomics can also further improve the 
understanding of the cellular drug disposition and response. The quantifica-
tion of drug transporters and metabolizing enzymes is useful for cell kinetic 
models. These models can be further developed by adding target expression 
and affinity data. This systems biology approach will facilitate the design of 
effective drugs that show minimal toxicity (i.e., drugs that are co-localized 
with the target, and that do not engage off-target proteins). The methodology 
presented in this study facilitates the validation of these models. 
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Svensk populärvetenskaplig sammanfattning 
De flesta läkemedel utövar sin effekt genom att binda till proteiner. Dessa så 
kallade målproteiner finns oftast inuti de celler man vill behandla. Där finns 
också de flesta proteiner som eliminerar läkemedel från kroppen genom att 
bryta ned dem, så kallade metaboliska enzymer. Dessutom binds läkemedlet 
ospecifikt till andra komponenter i cellen, t.ex. fettmolekyler i cellens mem-
bran. Det är bara den fraktion av läkemedelsmolekylen som inte är uppbun-
den som kan binda till målproteinet. Denna fria fraktion varierar mellan 
olika läkemedelsmolekyler. 
Historiskt har man ansett att den dos läkemedel som återfinns i fri form i 
blodet också kommer att nå sitt målprotein inne i cellen, något som senare 
visat sig vara felaktigt då läkemedelskoncentrationen i blodet inte sällan 
skiljer sig från den i cellen. Resultatet av detta kan bland annat vara att lä-
kemedlets effekt och eliminering från kroppen sker annorlunda än beräknat. 
Eftersom brist på effekt är den vanligaste orsaken till misslyckade kliniska 
läkemedelsprövningar är det viktigt att kunna bestämma den testade läkeme-
delsmolekylens fria fraktion inne i målcellen. Det är dock mycket svårt och 
inte etiskt försvarbart att utföra sådana tester rutinmässigt eftersom de skulle 
kräva att man tar vävnadsprover från friska organ hos försökspersonerna.  
I avhandlingen utvecklas en ny, enkel och småskalig provrörsmetod för 
att mäta koncentrationen av fritt läkemedel inuti målcellen. Inte oväntat vi-
sade det sig att mer fettlösliga, lipofila, läkemedel i större utsträckning fång-
ades upp och band till olika cellkomponenter. I dessa studier användes en 
lättodlad cellinje som ofta används i laboratorieforskning. Resultaten över-
ensstämde väl med tidigare studier i mera komplexa system, såsom levercel-
ler eller hjärnvävnad. Den nya provrörsmetoden har redan fått stort genom-
slag och används nu rutinmässigt av flera läkemedelsföretag i tidig läkeme-
delsforskning istället för djurvävnader. 
I nästa steg undersöktes hur så kallade transportproteiner påverkar läke-
medelsupptaget i cellen. Transportproteiner återfinns i cellernas membran 
och kan förflytta både kroppsegna ämnen och läkemedel in i och/eller ut ur 
cellerna. I denna studie användes transportören OATP1B1, som transporterar 
bland annat vanliga kolesterolsänkande läkemedel såsom statiner in i lever-
cellerna där de har sin effekt. Denna transportör bidrog till en ökad läkeme-
delskoncentration i cellen. Omvänt bidrog transportören P-gp, som transpor-
terar kroppsegna ämnen och läkemedel ut ur cellerna till att läkemedelskon-
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centrationen i cellen minskade. Olika transportörer hade därmed olika på-
verkan på koncentrationen av fria läkemedelsmolekyler inne i cellerna. 
I sista delen av avhandlingen studerades hur den uppmätta mängden fritt 
läkemedel inne i cellerna korrelerade till såväl läkemedlets bindning till 
målproteinet som dess effekt. Här användes olika substanser som hämmar 
tymidylatsyntas, ett viktigt målprotein inom cancerterapi. Försöken visade 
att ju mer fritt läkemedel som fanns inne i cellen, desto mer läkemedel kunde 
också binda sitt målprotein. Därefter studerades hur cellen i sig påverkas av 
upptagna läkemedelskandidater som visat sig vara aktiva (så kallade hits) i 
olika screeningskampanjer där 100 000-tals molekyler testas mot ett visst 
målprotein hos läkemedelsindustrin. Här inkluderades substanser för be-
handling av cancer, Alzheimers sjukdom och inflammation. Det visade sig 
att substanser som hade en hög fri koncentration inne i cellerna hade den 
starkaste effekten, medan de som hade en låg fri koncentration inne i cellen 
var ineffektiva. 
Sammanfattningsvis kan den nya enkla metoden bidra till att välja ut de 
läkemedelsmolekyler som har störst sannolikhet att vara effektiva inne i 
målcellerna och det är just därför som den omedelbart blivit attraktiv för 
läkemedelsindustrin. Dessutom kan man på ett tillförlitligt sätt förutse hur 
summan av olika transportproteiner och läkemedelsmetaboliserande enzy-
mer bidrar till läkemedelskoncentrationen i olika målceller. 
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Sumário em Português 
O interior da célula contém um grande número de proteínas com interesse 
farmacológico. Estas proteínas incluem não só alvos terapêuticos, mas 
também proteínas responsáveis pela eliminação de fármacos. É a fração livre 
de fármaco dentro da célula que está disponível para interações com essas 
proteínas. 
No passado, a concentração livre intracelular tem sido considerada igual à 
concentração de fármaco livre no plasma. Contudo, estudos recentes 
mostraram que vários fatores podem levar a que estas concentrações não 
sejam sempre idênticas. Ignorar esta diferença resulta numa má previsão da 
eliminação de fármacos do organismo a partir de experiências in vitro. Além 
disso, o desconhecimento da quantidade de fármaco que chega ao seu alvo 
terapêutico foi apontado como uma das principais causas para a falha clínica 
de fármacos. Por estas razões, métodos que possibilitem a medição de níveis 
intracelulares de fármaco livre têm o potencial de melhorar as previsões da 
farmacocinética e aumentar o número de fármacos que chega ao mercado. 
Esta tese descreve o desenvolvimento de um método simples e geral para 
a medição da concentração de fármaco livre no interior de células. O método 
desenvolvido baseou-se na determinação em paralelo da fração de fármaco 
livre intracelular (fu,cell) e da concentração intracelular total de fármaco (Kp). 
Estes dois parâmetros foram combinados para calcular a biodisponibilidade 
de fármaco dentro da célula (Fic). Para a determinação da fu,cell foi utilizada 
uma técnica miniaturizada de diálise. Os níveis intracelulares de fármaco 
foram medidos através da incubação de células com o composto até se 
atingir um equilíbrio. A quantificação de fármacos foi feita com recurso a 
cromatografia líquida acoplada a espectrometria de massa em tandem. Este 
método foi posteriormente aplicado em diversas moléculas e linhas celulares 
para estudar o efeito de transportadores de membrana nos níveis de fármaco 
disponíveis no interior da célula. Foi também estudado o efeito dos níveis 
intracelulares de fármaco na ligação a alvos terapêuticos e na resposta 
celular induzida pelo fármaco. 
A primeira parte da tese (Papers I e II) foca-se no desenvolvimento dos 
componentes individuais da metodologia numa linha celular simples (células 
HEK293). Em primeiro lugar, foi demonstrado ser possível utilizar apenas 
um valor de fu,cell para cada fármaco, uma vez que a ligação a estruturas 
celulares demonstrou ser independente da concentração de fármaco utilizada. 
Este resultado permitiu também avaliar a possibilidade de combinar vários 
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fármacos aquando da determinação da fu,cell. Uma vez que os valores da fu,cell 
não foram afetados quando medidos na presença de até oito compostos 
diferentes, foi possível acelerar o processo de medição e reduzir a carga 
experimental. De seguida, as propriedades moleculares que determinam a 
fu,cell foram estudadas. Fármacos lipofílicos e com uma elevada superfície 
disponível para interações apresentaram maior ligação a componentes 
celulares, enquanto fármacos com carga negativa e aromaticidade 
demonstraram menor ligação a elementos da célula. No conjunto, estes 
resultados sugerem que a fu,cell é o resultado da interação com membranas 
fosfolipídicas. Estes resultados foram também confirmados pela má 
correlação entre a fu,cell em células HEK293 e a ligação de fármacos às 
proteínas plasmáticas (este último sistema constituído principalmente por 
proteínas), mas boa correlação com a ligação a outros sistemas, como 
microssomas hepáticos, hepatócitos, ou cérebro (estruturas que incluem 
também lípidos na sua constituição). Após a medição da fu,cell, foi 
determinado que a maioria dos fármacos requerem 45 minutos para atingir 
um equílibrio de acumulação (Kp). Finalmente, foi determinada a Fic, 
utilizando os valores da fu,cell e da Kp. Nas células HEK293, que expressam 
baixos níveis de transportadores de membrana e de enzimas, a Fic esteve 
principalmente correlaccionada com a ionização dos fármacos. Fármacos 
com características básicas acumularam-se em compartimentos celulares 
com um pH baixo, como por exemplo lisosomas, e fármacos com 
características ácidas tiveram acesso limitado ao interior da célula devido ao 
baixo pH no interior comparado com o exterior. 
Na segunda parte da tese (Paper III), a metodologia desenvolvida foi 
aplicada ao estudo do efeito de transportadores de membrana na Fic. Para 
isso, células HEK293 foram transfetadas com o transportador de influxo 
“organic anion-transporting polypeptide 1B1” (OATP1B1). Nestas células, 
os substratos desta proteína demonstraram níveis mais elevados de Fic. Foi 
também demonstrado que este efeito depende da concentração de fármaco, já 
que a concentrações mais elevadas o transportador foi saturado. De seguida, 
o efeito contrário foi demonstrado para o transportador de efluxo “P-
glycoprotein” (P-gp), i.e., que a Fic de fármacos foi reduzida por este 
transportador. Finalmente, a metodologia foi utilizada em hepatócitos 
humanos mantidos em diferentes condições de cultura, de modo a alterar a 
expressão de transportadores. Foi observado que a Fic variou na direção 
prevista de acordo com a expressão de transportadores e das características 
do fármaco. Este resultado demonstrou que esta metodologia pode ser 
utilizada para medir o impacto de transportadores de membrana na Fic. 
A terceira parte da tese (Paper IV) mostrou a importância da concentração 
intracelular de fármaco para os níveis de ligação ao alvo terapêutico. Para o 
efeito, foram selecionados compostos que demonstraram ligar-se à timidilato 
sintase num ensaio biofísico denominado “cellular thermal shift assay” 
(CETSA). Os fármacos seleccionados necessitam de ser ativados antes de se 
 55
ligarem à enzima, i.e. pró-fármacos. Os níveis intracelulares destes fármacos 
e respetivos metabolitos foram medidos em função do tempo. Foi observada 
uma correlação entre os níveis de metabolito ativo e os níveis de 
estabilização do alvo terapêutico. Estes resultados demonstraram que a 
metodologia desenvolvida pode ser usada para estudar a cinética de 
distribuição e metabolismo intracelular de fármacos, sendo possível prever a 
extensão de ligação ao alvo terapêutico. 
Na quarta parte desta tese (Paper V), demonstrou-se a importância da Fic 
na resposta farmacológica celular. Para este efeito, foram utilizados três 
conjuntos de compostos. O primeiro conjunto foi baseado numa biblioteca 
pública de inibidores de cinases. Desta biblioteca foram selecionadas 
moléculas com potencial para inibir o crescimento de células e cujos alvos 
terapêuticos eram cinases localizadas no interior da célula. Foi observado 
que a Fic estava correlaccionada com a potência destes compostos em 
células. Este resultado demonstrou que estes fármacos necessitam de chegar 
ao seu alvo terapêutico para exercerem a sua atividade, i.e., fármacos que 
não atingem concentrações suficientemente elevadas dentro da célula não 
demonstraram atividade. De seguida foi utilizado um grupo de inibidores 
potentes da β-secretase 1 (BACE-1) com fraca resposta em células SH-
SY5Y. Uma baixa Fic destes compostos nas células explicou a ineficiência 
destas moléculas. Finalmente, estes resultados foram confirmados com um 
grupo de inibidores da “mitogen-activated protein kinase 14” (p38α). Tal 
como os inibidores da BACE-1, também estes compostos demonstraram Fic 
limitada em células mononucleares do sangue periférico e, por essa razão, 
baixa atividade nessas células. As razões para uma baixa atividade foram 
exploradas, tendo sido demonstrado que a presença de soro fetal bovino no 
meio de cultura limita a quantidade de fármaco disponível para entrar na 
célula. 
Em suma, a metodologia apresentada nesta tese é simples de utilizar e 
aplicável a diversos fármacos e a diversas linhas celulares. Esta técnica pode 
ser utilizada durante o processo de desenvolvimento de fármacos para 
garantir que os compostos atingem os seus alvos terapêuticos. Para além de 
permitir determinar a quantidade de fármaco disponível para interação com 
os alvos terapêuticos, a metodologia desenvolvida fornece informação 
importante para previsões de eliminação feitas a partir de experiências in 
vitro. No futuro, esta metodologia poderá ser expandida para incluir outros 
xenobióticos, como toxinas ambientais. 
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